Evidence map›Paper›PMID 26643336›Full record

ArticleAntimicrobial agents and chemotherapy2016

Abalone Hemocyanin Blocks the Entry of Herpes Simplex Virus 1 into Cells: a Potential New Antiviral Strategy.

Negar Talaei Zanjani, Monica Miranda-Saksena, Peter Valtchev, Russell J Diefenbach, Linda Hueston, Eve Diefenbach, Fareed Sairi, Vincent G Gomes, Anthony L Cunningham, Fariba Dehghani

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Anti-viral activity ofInternational journal of ophthalmology · 2021
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Negar Talaei ZanjaniSchool of Chemical and Biomolecular Engineering, The University of Sydney, New South Wales, Australia.
Monica Miranda-SaksenaCentre for Virus Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.
Peter ValtchevSchool of Chemical and Biomolecular Engineering, The University of Sydney, New South Wales, Australia.
Russell J DiefenbachCentre for Virus Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.ORCID http://orcid.org/0000-0002-8433-4336
Linda HuestonArbovirus Emerging Diseases Unit, Centre for Infectious Diseases and Microbiology Laboratory Services, Pathology West-ICPMR Westmead, New South Wales, Australia.
Eve DiefenbachProtein Core Facility, The Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.
Fareed SairiSchool of Chemical and Biomolecular Engineering, The University of Sydney, New South Wales, Australia.
Vincent G GomesSchool of Chemical and Biomolecular Engineering, The University of Sydney, New South Wales, Australia.
Anthony L CunninghamCentre for Virus Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia tony.cunningham@sydney.edu.au fariba.dehghani@sydney.edu.au.
Fariba DehghaniSchool of Chemical and Biomolecular Engineering, The University of Sydney, New South Wales, Australia tony.cunningham@sydney.edu.au fariba.dehghani@sydney.edu.au.
The University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A marine-derived compound, abalone hemocyanin, from Haliotis rubra was shown to have a unique mechanism of antiviral activity against herpes simplex virus 1 (HSV-1) infections. In vitro assays demonstrated the dose-dependent and inhibitory effect of purified hemocyanin against HSV-1 infection in Vero cells with a 50% effective dose (ED50) of 40 to 50 nM and no significant toxicity. In addition, hemocyanin specifically inhibited viral attachment and entry by binding selectively to the viral surface glycoproteins gD, gB, and gC, probably by mimicking their receptors. However, hemocyanin had no effect on postentry events and did not block infection by binding to cellular receptors for HSV. By the use of different mutants of gD and gB and a competitive heparin binding assay, both protein charge and conformation were shown to be the driving forces of the interaction between hemocyanin and viral glycoproteins. These findings also suggested that hemocyanin may have different motifs for binding to each of the viral glycoproteins B and D. The dimer subunit of hemocyanin with a 10-fold-smaller molecular mass exhibited similar binding to viral surface glycoproteins, showing that the observed inhibition did not require the entire multimer. Therefore, a small hemocyanin analogue could serve as a new antiviral candidate for HSV infections.

Indexed as

AnimalsAntiviral AgentsBinding SitesChlorocebus aethiopsDose-Response Relationship, DrugGastropodaGlycoproteinsHemocyaninsHerpesvirus 1, HumanVero CellsAntiviral AgentsGlycoproteinsHemocyanins

Identifiers

PMID26643336
PMCPMC4750698
OpenAlexW2315513762

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.